Platelet-to-lymphocyte ratio in kidney diseases: a review of current evidence
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The platelet-to-lymphocyte ratio (PLR) is an emerging systemic inflammation marker that has shown prognostic and diagnostic utility across oncology, cardiovascular, and autoimmune disorders. Because inflammation and renal pathology are mutually reinforcing processes that accelerate progression toward end‑stage kidney disease. In recent years, several studies have indicated that PLR has important value in the occurrence, progression, and therapeutic prognosis of kidney diseases. This review summarizes current evidence on PLR across settings including acute kidney injury (AKI), chronic kidney disease (CKD), primary and secondary nephropathies, and renal replacement therapy, and evaluates its role in prognostic assessment. We discuss the potential of PLR as an accessible adjunct for early diagnosis and prognosis in kidney disease, providing a new marker to support timely and effective treatment of renal disease.
Fields of Study & Subjects
Inflammatory Biomarkers in Disease Prognosis
Dialysis and Renal Disease Management
Acute Kidney Injury Research
Publication details
- Journal / source
- DOAJ (DOAJ: Directory of Open Access Journals)
- Publication date
- 1 March 2026
- Language
- ZH